Stocktoria
Cipla Limited CIPLA.NS
IN · National Stock Exchange of India · XNSE · stock · Healthcare · website
Cipla Limited financials (annual, from 10-K)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ₹277.1B | ₹271.5B | ₹254.5B | ₹224.7B |
| Gross profit | ₹172.6B | ₹173.8B | ₹158.5B | ₹135.1B |
| R&D expense | ₹5.2B | ₹3.8B | ₹4.3B | ₹3.9B |
| SG&A expense | ₹30.9B | ₹29.6B | ₹27.8B | ₹26.2B |
| Operating income | ₹48.5B | ₹61.4B | ₹53.7B | ₹40.2B |
| Interest expense | ₹482.3M | ₹440.2M | ₹711.3M | ₹945.6M |
| Income tax | ₹13.5B | ₹15.3B | ₹15.5B | ₹12.0B |
| Net income | ₹38.8B | ₹52.7B | ₹41.2B | ₹28.0B |
| EPS (diluted) | — | ₹65.24 | ₹51.01 | ₹34.69 |
| Operating cash flow | ₹39.4B | ₹50.0B | ₹41.3B | ₹32.4B |
| Free cash flow | ₹8.6B | ₹34.6B | ₹27.8B | ₹20.5B |
| Cash & equivalents | ₹10.2B | ₹5.9B | ₹6.4B | ₹6.3B |
| Inventory | ₹66.0B | ₹56.4B | ₹52.4B | ₹51.6B |
| Total assets | ₹425.0B | ₹373.9B | ₹327.2B | ₹294.6B |
| Total liabilities | ₹79.8B | ₹61.0B | ₹59.2B | ₹57.5B |
| Shareholders' equity | ₹344.3B | ₹311.9B | ₹267.1B | ₹234.1B |
Growth · year-over-year · Revenue CAGR 7.2%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | +2.1% | +6.7% | +13.2% | — |
| Net income growth | -26.4% | +27.9% | +47.1% | — |
| EPS growth | — | +27.9% | +47.0% | — |
| Free cash flow growth | -75.1% | +24.1% | +35.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · IN · as of 2026-03-31. Figures in INR; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.